With July around the corner, investors will be closely tracking the FDA's upcoming decisions on therapies targeting conditions ranging from breast cancer and IgA nephropathy to multiple myeloma, ADHD, and wet AMD.
The following biotech companies are awaiting FDA decisions in July.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com